Dhaka, July 29 -- INBRAIN Neuroelectronics has announced promising interim results from the world's first human clinical study of its graphene-based brain-computer interface (BCI), marking a major leap forward in real-time, precision neurology.

The study, conducted at the Manchester Centre for Clinical Neurosciences (Northern Care Alliance NHS Foundation Trust) and sponsored by the University of Manchester, is assessing the safety and performance of INBRAIN's BCI technology during brain tumor surgeries.

Interim findings from the first four patients in the 8-10 patient trial show no device-related adverse events, affirming the primary safety goal. The ultra-thin, flexible graphene electrodes successfully recorded high-resolution neural s...